Inventor · disambiguated record
Joseph Chin
Also filed as: CHIN JOSEPH · CHIN JOSEPH L
8 granted patents·2 pending applications·572 citations·filing 1996–2006
90Inventor score
Files withPRAECIS PHARM INC6LONDON HEALTH SCI CT RES INC1PARAECIS PHARMACEUTICALS INC1PROCYON BIOPHARMA INC1
Top patents by PatentIndex Score
10 records- 0196US5854204AAβ peptides that modulate β-amyloid aggregationPRAECIS PHARM INC·Filed 1996·Granted Dec 29, 1998·230 cites·10 claims
- 0292US6303567B1Modulators of β-amyloid peptide aggregation comprising D-amino acidsPRAECIS PHARM INC·Filed 1996·Granted Oct 16, 2001·142 cites·135 claims
- 0392US5985242AModulators of β-amyloid peptide aggregation comprising D-amino acidsPRAECIS PHARM INC·Filed 1997·Granted Nov 16, 1999·120 cites·19 claims
- 0485US6689752B2Modulators of β-amyloid peptide aggregation comprising D-amino acidsPRAECIS PHARM INC·Filed 2001·Granted Feb 10, 2004·17 cites·21 claims
- 0584US6277826B1Modulators of β-amyloid peptide aggregation comprising D-amino acidsPRAECIS PHARM INC·Filed 1999·Granted Aug 21, 2001·36 cites·11 claims
- 0679US7175828B2Modulators of β-amyloid peptide aggregation comprising D-amino acidsPRAECIS PHARM INC·Filed 2003·Granted Feb 13, 2007·4 cites·13 claims
- 0755US2007248996A1Modulators of beta-amyloid peptide aggregation comprising D-amino acidsPARAECIS PHARMACEUTICALS INC·Filed 2006·Application pending·0 cites
- 0854US6107103AAssay for PSP94 proteinPROCYON BIOPHARMA INC·Filed 1997·Granted Aug 22, 2000·23 cites·12 claims
- 0939US7732564B2Serum tumor marker in rodent prostate cancer modelsLONDON HEALTH SCI CT RES INC·Filed 2006·Granted Jun 8, 2010·0 cites·1 claims
- 1037US2003110522A1Generation of transgenic mouse models for the development of prostate cancer using regulatory regions of the PSP94 geneFiled 2002·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Joseph Chin files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →